Brain+

0.014

DKK

0 %

Less than 1K followers

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

0%

-7.69%

-41.94%

-65.53%

-69.13%

-73.55%

-97.57%

-

-98.95%

Brain+ are a pharmaceutical company. The company specializes in research and development for the treatment of dementia and Alzheimer's. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with the largest presence in Europe. Brain+ is headquartered in Copenhagen.

Market cap

16.31M DKK

Turnover

22.9K DKK

Revenue

200K

EBIT %

-5,830 %

P/E

-

Dividend yield-%

-

Financial calendar

28.8

2025

Interim report Q2'25

All

Press releases

3rd party

ShowingAll content types

Regulatory press release6/24/2025, 12:11 PM

Brain+ A/S announces first day of trading in new shares following the TO 5 warrant exercise

Regulatory press release6/18/2025, 9:22 AM

Brain+ A/S announces the outcome of its series TO 5 warrant exercise

Regulatory press release6/10/2025, 7:58 AM

Brain+ A/S has received commitments to cover 100% of its TO 5 warrants, securing DKK 5.9 million in gross proceeds

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release6/6/2025, 2:56 PM

Invitation to investor webinar featuring Antony Hall: How new CST evidence and UK dementia care quality focus underscore the relevance and potential of Ayla

Press release6/6/2025, 8:51 AM

New research underscores the effects of Cognitive Stimulation Therapy, supporting its role for UK care homes to comply with care quality statements

Press release6/5/2025, 9:49 AM

Brain+ signs agreement with UK care home group Majesticare deploying Ayla for effective dementia care

Regulatory press release6/2/2025, 1:49 PM

Brain+ A/S announces the exercise price for its warrants of series TO 5

Regulatory press release5/30/2025, 2:22 PM

Brain+ A/S - Minutes of Annual General Meeting

Press release5/28/2025, 6:46 AM

Brain+ A/S: Leading UK dementia care authority, Antony Hall, joins Brain+ as Strategic Advisor

Press release5/26/2025, 6:48 AM

Brain+ A/S: Brain+ signs its second UK sales agreement on Ayla with Park Homes UK Group

Regulatory press release5/15/2025, 9:27 PM

Brain+ A/S convenes the Annual General Meeting for 2025

Press release5/5/2025, 7:00 AM

Brain+ A/S: Brain+ selected for the NHS Dementia Innovators Programme in the UK

Regulatory press release4/29/2025, 6:19 PM

Brain+ A/S: Brain+ publishes its Annual Report for 2024

Regulatory press release4/16/2025, 9:15 AM

Brain+ A/S: Brain+ appoints CCO Devika Wood as new CEO

Regulatory press release4/9/2025, 6:50 AM

Brain+ A/S: Brain+ announces directed issue of units to convertible loan providers and guarantors

Press release4/3/2025, 6:41 AM

Brain+ A/S: Contract signed with Copenhagen Municipality on extended and expanded access to Ayla

Regulatory press release4/2/2025, 6:47 AM

Brain+ A/S: Brain+ announces outcome of unit rights issue

Press release3/26/2025, 7:35 AM

Brain+ A/S informs of last day to subscribe in its ongoing rights issue of units

Press release3/25/2025, 11:56 AM

Brain+ A/S: Brain+ to close first UK Care Home partnership contract with Southcare Homes Group

Press release3/19/2025, 1:44 PM

Brain+ A/S: Invitation to investor webinar to present new Board Observer, sales pipeline progress and ongoing Unit Rights Issue

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.